We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BELLUS Health Inc | TSX:BLU | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 19.48 | 19.46 | 19.52 | 0 | 01:00:00 |
From May 2022 to May 2024
By Colin Kellaher
Shares of Bellus Health Inc. nearly doubled in premarket trading Tuesday after the late-clinical-stage biopharmaceutical company agreed to be acquired by U.K. drug major GSK PLC for about $2 billion.
GSK said it would pay $14.75 a share in cash for Bellus, more than double Monday's closing price of $7.26 for U.S.-listed shares of the Laval, Quebec, company.
Bellus shares also are listed in Canada, and the deal consideration equates to roughly 19.71 Canadian dollars, also more than double Monday's closing price of C$9.71 for Toronto-listed shares of Bellus.
The deal is slated to close by the third quarter.
U.S.-listed shares of Bellus were recently up 98% to $14.34 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 18, 2023 06:09 ET (10:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year BELLUS Health Chart |
1 Month BELLUS Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
